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The Pd-catalyzed N-arylation method for the synthesis of eighteen N,1-diaryl-1H-tetrazol-5-amine 
derivatives is reported. By running the reactions at 35 ºC, compounds were isolated as single isomers 
since the undesired Dimroth rearrangement was completely suppressed. Furthermore, the Dimroth 
rearrangement of N,1-diaryl-1H-tetrazol-5-amines was rationalized by conducting comprehensive 
experiments and NMR analysis as well as DFT calculations of thermodynamic stability of the 
compounds. It was established that the Dimroth rearrangement is thermodynamically controlled and the 
equilibrium of the reaction is determined by the stability of the corresponding isomers. The mechanism 
was investigated by additional DFT calculations and the opening of the tetrazole ring was shown to be 
the rate-determining step. By maneuvering Pd-catalyzed N-arylation and the subsequent Dimroth 
rearrangement two more N,1-diaryl-1H-tetrazol-5-amine derivatives were acquired, that otherwise 
cannot be synthesized by employing the C–N cross-coupling reaction. 
 




The tetrazole scaffold is a well-known motif in bioactive compounds. This heterocyclic moiety can be 
found in FDA approved drugs, such as Losartan, an angiotensin II receptor blocker used to treat high 
blood pressure,1 or Cefonicid, an antibiotic active against Gram-negative rods.2 As its derivative, the 
1H-tetrazol-5-amine scaffold is an important pharmacophore in drug discovery and development. 
Recently, 1-aryl-5-arylamino-1H-tetrazoles have been shown to possess antitubercular potential 
(compound 1, Figure 1),3 while other 1-aryl-5-alkylamino derivatives are proven to be active against 
Gram-positive and Gram-negative strains (compound 2, Figure 1).4 There have also been reports on 
antiallergic5 and antidiabetic6 activity of aminotetrazoles. Applications outside medicinal chemistry 
include protection against steel corrosion (compound 4, Figure 1),7 as well as uses in coordination 
chemistry as ligands8 and in synthetic chemistry as reactive intermediates.9 Additionally, Krishnan et 
al. demonstrated the utility of aminotetrazole-functionalized nanoparticle composites for the removal of 
dyes and detection of heavy metal ions.10  
 
 
Figure 1. Selected molecules containing an aminotetrazole moiety 
 
The most common approach for the synthesis of the N,1-diaryl-1H-tetrazol-5-amines is based on the 
formation of the tetrazole ring from N-substituted acyclic precursors,11 however, this methodology 
usually provides the mixture of isomeric compounds.9b,11d Having in mind the importance of this class 
of heterocycles, and the aforementioned difficulties, the development of highly selective synthetic 
method presents a challenge.  
RESULTS AND DISCUSSION 
The palladium-catalyzed formation of the C–N bond between aryl-halides and amines is one of the 
most important reactions in modern organic chemistry and drug development process12,13 and under 
classical Buchwald-Hartwig reaction conditions, the reaction mixture is heated between 80 and 120 
degrees Celsius.14,15 As a continuation of our previous research in the chemistry of tetrazoles, we 
sought to synthesize new 1-aryl-N-aryl-1H-tetrazol-5-amines. Applying previously used reaction 
conditions16 on 5a and 6a yielded a mixture of two regioisomeric compounds 7a and 7b (Table 1, entry 
4). It is worth mentioning that compounds 7a and 7b could not be separated by standard 
chromatographic techniques. In-depth analysis showed that the mixture of compounds is a result of N-
arylation followed by the Dimroth rearrangement. Therefore, our next step was to optimize the reaction 
conditions to suppress the rearrangement reaction. By lowering the reaction temperature to 80 ºC the 
yield dropped and the rearrangement product 7b was still the dominant one (Table 1, entry 3). Running 
the reaction at room temperature yielded solely the desired product 7a albeit in low yield, while starting 
compound 5a was recovered (Table 1, entry 1).  Raising the temperature to 35 ºC resulted in the 
formation of the desired product 7a, which was obtained in high yield, whilst the rearrangement 
product 7b was not detected (Table 1, entry 2). Additionally, we wanted to examine whether raising the 
reaction temperature to 130 ºC would impact the ratio of the products and yield only one product 
(Table 1, entry 5). We concluded that the higher temperatures do not play a significant role in the 
product distribution of the Dimroth rearrangement and that, perhaps, structural parameters govern the 
outcome of the reaction. 
 
Table 1. Temperature controlled outcome of Pd-catalyzed N-arylation 
 
entry temperature (°C) yield (%) isomer ratiob 
1 r.t. 33% 1 : 0 
2 35 98% 1 : 0 
3 80 86%d 1 : 3.5 
4 105 95%d 1 : 3.5 
5 130 88%c 1 : 3.0 
aReactions conditions: 5a (1.05 equiv), 6a (1.0 equiv), Pd2(dba)3 (10 mol % Pd), t-BuXPhos (20 mol %), NaOt-Bu (1.05 
equiv), 1,4-dioxane, 24 h, Ar. bIsomer ratio by 1H NMR spectroscopy. cYield of a mixture of isomers. 
 
In order to investigate the scope of the palladium catalyzed N-arylation reaction at 35 ºC, we 
synthesized a series of 17 additional derivatives 7b-7r (Table 2). These compounds would later be used 
as substrates for the rearrangement reaction and the detailed analysis of the relationship between the 
structural parameters and the isomer distribution. A series of aryl bromides and 1-aryl-1H-tetrazol-5-
amines, including those with an electron-donating group (‒OMe) and with electron-withdrawing 
groups (‒NO2, ‒CF3) were transformed into the desired products in good to excellent yields (Table 2, 
7b-7h). Reactions of halogen substituted compounds 5 and 6 also gave the corresponding products 7i-
7n in high yields, showing excellent selectivity towards bromine atom. When sterically demanding 2-
bromo-1,3,5-trimethylbenzene 6i was reacted with 5a, the desired product 7q was obtained in 27% 
yield. The scope of this method was further expanded by utilizing heteroaryl bromides or 1-heteroaryl-
1H-tetrazol-5-amines. The desired pyridine substituted tetrazoles 7o and 7p were obtained in 84% and 
69% yield, respectively. By reacting 2,4-dichloropyrimidine 6j with 1-phenyl-1H-tetrazol-5-amine 5a 
in the presence of Pd2(dba)3, t-BuXPhos as a ligand and K2CO3 as a base in 1,4-dioxane, product 7r 
was obtained in 44% yield. However, by changing the ligand to XantPhos, the yield of the desired 
product 7r was raised to 63%. Unfortunately, there was no reaction when 3-bromo-1-tosyl-1H-indole 
6k was employed as a substrate (Table 2, 7s). This indole derivative has been shown in literature to be 
problematic in this type of reactions. Notably, the reaction scale could be increased to 1 mmol, shown 
on the example of the compound 7h. It is worth mentioning that all the products were isolated as single 
isomers, with no detection of side-products, showcasing the selectivity of this method and the hindering 
of the subsequent rearrangement reaction. This method allows for the synthesis of any isomer as a 
single compound as illustrated for 7b (Table 1 and Table 2). As most of the desired compounds were 
synthesized in good to excellent yields, with broad substrate scope, this method could be utilized for 
further functionalization and the synthesis of more complex compounds. 
  
 
Table 2. Substrate scope for palladium catalyzed N-arylationa 
 
 
aReactions conditions: 5 (1.05 equiv), 6 (1.0 equiv), Pd2(dba)3 (10 mol % Pd), t-BuXPhos (20 mol %), NaOt-Bu (1.05 
equiv), 1,4-dioxane, 35 °C, 24 h, Ar. bReaction performed on 1.1 mmol scale. cK2CO3 (1.05 eq) used as a base and 
XantPhos  (20 mol%) used as a ligand. 
 
Since Dimroth rearrangement is successfully employed as a method of attaining various heterocyclic 
structures, applied to industrial processes and even observed in biological systems, as a continuation of 
this research, we wanted to further study the said transformation on this heterocyclic system.17 Dimroth 
rearrangement of 1H-tetrazole-5-amine derivatives was first observed in 1953,18,19 during heating of 
various monosubstituted 5-aminotetrazoles and some 5-alkyl-1-aryl-1H-tetrazole-5-amines. A similar 
transformation was noticed by Dimroth in 1H-1,2,3-triazole-5-amine derivatives,20 and later recognized 
as a valuable method for acquiring some previously unavailable aminotetrazoles.21 The occurrence of 
Dimroth rearrangement of tetrazoles still seems to be somewhat neglected in modern organic synthesis, 
appearing more often as an unexpected22 or unwanted23 side reaction than as the desired 
transformation.24 
With a set of N,1-diaryl-1H-tetrazol-5-amines shown in Table 2, we sought to explore the outcome of 
Dimroth rearrangement. Firstly, the reaction conditions were studied. When compound 7a was heated 
in 1,4-dioxane (105 ºC, 24 h) without a palladium source and a ligand either in the presence of NaOt-
Bu (1.05 equiv) or in the absence of the base, the isomer ratio remained the same, meaning that neither 
the base nor palladium play a role in the rearrangement. Changing the solvent to CD3OD, CDCl3, C6D6 
and DMSO-d6 and heating 7a in the corresponding solvent at 105 ºC for 24 h did not alter the ratio of 
the isomers, always giving 7a : 7b = 1 : 3.5 ratio.  This strongly suggested that the solvent does not 
play an important role in the outcome of the reaction. Next, in order to investigate the influence of 
structural characteristics on the ratio of the isomers, we subjected all compounds to Dimroth 
rearrangement, by heating them at 105 ºC for 24h in either 1,4-dioxane or DMSO-d6 (Table 3). Based 
on the acquired results, several conclusions could be made. Primarily, the electronic effects of 
substituents play an important role. Compounds containing a phenyl core with electron-donating 
groups on the endocyclic nitrogen of the tetrazole ring will always be in excess after the reaction. This 
means that electron-withdrawing substituents show a preference for the exocyclic position. An additive 
effect could also be observed, when comparing entry 1 and entry 6 as well as entry 15 and entry 18 
(Table 3). Additionally, the position of the substituent (m-F vs p-F) also impacts the outcome of the 
reaction (entries 10 and 12) - the difference in the isomer ratio of this pair of compounds can be 
attributed to the stronger influence of the inductive effect. Three methyl groups (entry 17) greatly affect 
the rearrangement with almost a complete conversion of one isomer to another. It is important to 
outline that the isomer ratio in the Dimroth reaction remained the same, regardless of which single 
isomer was used as a starting compound. This suggests that the ratio was dictated by the stability of the 
compounds, implying a thermodynamic control of the reaction. We next sought to determine the 
temperature at which the reaction initiates. To achieve this, we chose a pair of substrates 7m and 7n 
and we recorded the 1H NMR spectra while the sample was gradually heated (~1 ºC/min) inside the 
NMR spectrometer (see the Supporting Information, Tables S1 and S2). We observed that 7n begins to 
transform into 7m at 80 ºC, while for the corresponding 7m we detected the formation of 7n only at 99 
ºC. From the experimental data, we concluded that the transformation of different starting isomers 
proceeds at different rates at the same temperature presumably due to the difference in the activation 
energies. The two isomers exist in equilibrium and the stability of the compounds determines the 
position of the equilibrium between the two regioisomers. This hypothesis was further investigated and 
reinforced by in silico methods (Table 3, Table S3). 
 
Table 3. Substrate scope for Dimroth rearrangementa 
 
entry R1 R2 Ratio
b of A:B Ratio of isomers (based on ΔrG)
c 
1 H 4-OMe 22:78 
7a:7b=13:87 
2 4-OMe H 78:22 
3 H 4-NO2 100:0 
7c:7d=99:1 
4 4-NO2 H 0:100 
5 4-OMe 4-NO2 100:0 
7e:7f=100:0 
6 4-NO2 4-OMe 0:100 
7 H 3-CF3 89:11 
7g:7h=88:12 
8 3-CF3 H 12:88 
9 H 3-F 79:21 
7i:7j=80:20 
10 3-F H 25:75 
11 H 4-F 50:50 
7k:7l=51:49 
12 4-F H 50:50 
13 H 3-Cl 81:19 
7m:7n=85:15 
14 3-Cl H 19:81 
15 H 3-pyr 78:22 7o:7p=90:10 
16 3-pyr H 22:78 
17 H Mes 4:96 A:B=<1:>99 
18 H 4-2-Cl-pyrimidine 100:0 A:B=76:24 
aReaction conditions: 7 (10 mg), 1,4-dioxane or DMSO-d6 (0.5 mL), 105 °C, 24 h. 
bIsomer ratio by 1H NMR spectroscopy 
(see the Supporting Information). cBased on the difference in Gibbs free energies of isomers (T=378.15 K) calculated at 
BLYP-D4/def2-TZVP(-f)-SMD (dioxane) level of theory. 
 
Based on all the acquired data – experimental results, DFT calculations and NMR experiments, we 
propose the mechanism of Dimroth rearrangement (Scheme 1, Figure 2, Figure S1). The transformation 
proceeds through a thermally induced ring opening-ring closing process. The conformational changes 
arising from the rotation of the C5–N bond were chosen, for the sake of clarity, to represent the first 
and the last step, although they can occur at any stage of the reaction pathway. Temperature-induced 
opening of the tetrazole ring leads to a substituted guanylazide II, which can transform further to IV 
via bond rotation-proton transfer (via intermediate III) or proton transfer (intermediate VI) followed by 
bond rotation. The cyclization of guanylazide II and IV to I and V, respectively, are 
thermodynamically favorable. Notably, compound with an electron-rich aromatic ring in N1 position 
7b is more stable than the other isomer 7a (Figure 2). It is also worth mentioning that the relative 
energies of II and IV are different and that the less stable IV has lower activation energy for 
cyclization to 7b. This is in agreement with the fact that the electron-donating methoxy group 
destabilizes IV. Overall, it can be concluded that the reaction is thermodynamically controlled and that 
ring-opening is the rate-determining step. To the best of our knowledge, this is the first time that the 
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Scheme 1. Proposed mechanism for Dimroth rearrangement. 
 
 
Figure 2. Calculated reaction profile for the Dimroth rearrangement of 7a and 7b. Gibbs free energies 
(in kcal/mol relative to 7a) at 378.15 K, obtained using the BLYP-D4/def2-TRVP(-f)-SMD(dioxane) 
level of theory. 
 
In order to further demonstrate the control of the Dimroth rearrangement and the applicability of the 
synthesized N,1-diaryl-1H-tetrazol-5-amines, compounds 7t and 7u were synthesized (Scheme 2). 
Compound 7d was converted into 7c using the conditions for Dimroth rearrangement (Table 3). 
Compound 7t was obtained in quantitative yield by reducing the nitro group of 7c, under hydrogen 
atmosphere (1 atm) using Pd/C (5 mol % Pd) as a catalyst. By exploiting the selectivity of Dimroth 
rearrangement, compound 7t was quantitatively converted into the compound 7u when it was heated in 
1,4-dioxane at 105 ºC for 24h (Scheme 2). This result is in a good agreement with the results obtained 
by DFT calculations, where the ratio of isomers for 7t:7u from Gibbs free energies is 4:96 (calculated 
at BLYP-D4/def2-TZVP(-f)-SMD(dioxane) level of theory at T=378.15 K). To further confirm the 
structure of 7u, compound 7d was reacted with hydrogen in the presence of Pd/C (5 mol % Pd) and 7u 
was obtained in quantitative yield. It is important to outline that compounds 7t and 7u cannot be 
efficiently synthesized through Pd-catalyzed N-arylation of 1-phenyl-1H-tetrazol-5-amine 5a or 1-(4-
aminophenyl)-1H-tetrazol-5-amine, respectively, as there is a competing effect between the 
aminotetrazole and aniline moiety. Additionally, amino group represents another possible point for 
further derivatization of N,1-diaryl-1H-tetrazol-5-amines. 
 
 
Scheme 2. Synthesis of 7t and 7u 
 
CONCLUSIONS 
In conclusion, we used Pd-catalysed N-arylation to synthesize a set of N,1-diaryl-1H-tetrazol-5-amines. 
By controlling the reaction temperature, unwanted Dimroth rearrangement was prevented and the 
desired compounds were isolated as single isomers. Better insight into the Dimroth rearrangement was 
gained by further studying the isomer distribution at elevated temperatures. The equilibrium was found 
to be a function of the thermodynamic stability of the products. The thermodynamic control of the 
reaction, as well as the distribution of isomers in the Dimroth rearrangement, was confirmed by in 
silico methods. Additionally, DFT calculations were used to propose a reaction mechanism, elucidating 
the ring-opening as the rate-limiting step. Finally, with the newly gained understanding of the structural 
parameters that determine the rearrangement outcome, we applied a sequence of reactions to synthesize 
compounds that cannot otherwise be selectively obtained through Pd-catalyzed reactions. 
 
EXPERIMENTAL SECTION 
General Information.  
Unless stated otherwise, all solvents and reagents were obtained from commercial sources and used 
without further purification. Dry-flash chromatography was performed on SiO2 (0.018–0.032 mm). 
Melting points were determined on a Boetius PMHK apparatus and are not corrected. IR spectra were 
recorded on a Thermo-Scientific Nicolet 6700 FT-IR Diamond Crystal instrument. 1H and 13C NMR 
spectra were recorded on a Bruker Ultrashield Avance III spectrometer (at 500 and 125 MHz, 
respectively) and Varian spectrometer (at 400 and 100 MHz, respectively). Chemical shifts are 
expressed in parts per million (ppm) on the (δ) scale. Chemical shifts were calibrated relative to those 
of the solvent. All new compounds were analyzed by high resolution tandem mass spectrometry using 
LTQ Orbitrap XL (Thermo Fisher Scientific Inc., USA) mass spectrometer. The sample was dissolved 
in MeCN and it was injected directly. Ionization was done in positive mode on heated electrospray 
ionization (HESI) probe. HESI parameters were: spray voltage 4.7 kV, vaporizer temperature 60 °C, 
sheath and auxiliary gas flow 24 and 10 (arbitrary units), respectively, capillary voltage 49 V, capillary 
temperature 275 °C, tube lens voltage 80 V, resolution (at m/z 400): 30000. 
 
Synthesis. 
Compounds 1-phenyl-1H-tetrazol-5-amine (5a),25a 1-(4-methoxyphenyl)-1H-tetrazol-5-amine (5b),25b 
1-(4-nitrophenyl)-1H-tetrazol-5-amine (5c),25a 1-(3-chlorophenyl)-1H-tetrazol-5-amine (5g),25c 3-
bromo-1-tosyl-1H-indole (6k)25d were synthesized according to the previously reported procedures. 
Compounds 1-bromo-4-methoxybenzene (6a), bromobenzene (6b), 1-bromo-4-nitrobenzene (6c), 1-
bromo-3-(trifluoromethyl)benzene (6d), 1-bromo-3-fluorobenzene (6e), 1-bromo-4-fluorobenzene (6f), 
1-bromo-3-chlorobenzene (6g), 3-bromopyridine (6h), 2-bromo-1,3,5-trimethylbenzene (6i), 2,4-




1-(3-(Trifluoromethyl)phenyl)-1H-tetrazol-5-amine (5d). A round-bottom reaction flask equipped 
with reflux condenser was charged with 3-(trifluoromethyl)aniline (772 µL, 6.20 mmol, 1.0 equiv), 
NaN3 (444 mg, 6.83 mmol, 1.1 equiv), triethyl orthoformate (3.1 mL, 19 mmol, 3 equiv) and glacial 
AcOH (28.4 mL, 49.6 mmol, 8 equiv). The mixture was stirred and heated at 80 °C in an oil bath for 4 
h after which it was cooled to room temperature and diluted with brine (125 mL). Solid Na2CO3 was 
added to the stirring solution until the gas evolution ceased. The formed precipitate was separated by 
filtration, washed with H2O and dried. The product, 1-(3-(trifluoromethyl)phenyl)-1H-tetrazole, was 
used in the next step without any additional purification. 
A round-bottom reaction flask was charged with 1-(3-(trifluoromethyl)phenyl)-1H-tetrazole (1.000 g, 
4.670 mmol, 1.0 equiv), NaN3 (455 mg, 7.00 mmol, 1.5 equiv), NaOH (280 mg, 7.00 mmol, 1.5 equiv), 
Et3N (1.3 mL, 9.3 mmol, 2 equiv) and i-PrOH (1.57 mL, 18.7 mmol, 4 equiv) after which DMSO (3.3 
mL, 46.7 mmol, 10 equiv) was added dropwise. The reaction mixture was stirred at room temperature 
until the gas evolution ceased (2 h) and then it was treated with glacial AcOH (800 μL, 14.0 mmol, 3 
equiv). The resulting solution was stirred and heated at 80 °C in an oil bath for 2 h, cooled to room 
temperature and diluted with brine (60 mL). The formed precipitate was separated by filtration, washed 
with H2O and dried. Compound 5d was obtained as a pale yellow powder (865 mg, 81%); m.p. 129 – 
130 °C. IR (ATR) = 3317, 3142, 1658, 1582, 1505, 1477, 1347, 1322, 1308, 1277, 164, 1144, 1086, 
1056, 903, 806, 702 cm-1. 1H NMR (400 Hz, DMSO-d6): δ 7.97 – 7.81 (m, 4H), 7.05 (s, 2H) ppm. 
13C{1H} NMR (100 Hz, DMSO-d6): δ 155.1, 134.1, 131.2, 130.5 (q, J = 33 Hz), 128.4, 126.1 (q, J = 4 
Hz), 123.6 (q, J = 272 Hz), 121.2 (q, J = 4 Hz) ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ Calcd. for 
C8H7F3N5
+ 230.0648; Found 230.0654. 
 
1-(3-Fluorophenyl)-1H-tetrazol-5-amine (5e). Following the procedure described for the 5d, 
compound 5e was obtained as a pale yellow solid (369 mg, 46%) starting from 3-fluoroaniline (498 
mg, 4.48 mmol); m.p. 146 – 147 °C. IR (ATR) = 3313, 3125, 1660, 1607, 1577, 1502, 1471, 1312, 
1200, 1140, 1093, 875, 792, 677 cm-1. 1H NMR (400 Hz, CD3OD): δ 7.69 – 7.59 (m, 1H), 7.48 – 7.37 
(m, 2H), 7.36 – 7.28 (m, 1H) ppm. 13C{1H} NMR (100 Hz, CD3OD): δ 164.4 (d, J = 247 Hz), 156.4, 
136.2 (d, J = 10 Hz), 132.8 (d, J = 9 Hz), 121.0 (d, J = 4 Hz), 117.6 (d, J = 22 Hz), 112.7 (d, J = 25 Hz) 
ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ Calcd. for C7H7FN5
+ 180.0680; Found 180.0687. 
 
1-(4-fluorophenyl)-1H-tetrazol-5-amine (5f). Following the procedure described for the 5d, 
compound 5f was obtained as a pale yellow solid (328 mg, 45%) starting from 4-fluoroaniline (448 mg, 
4.03 mmol); m.p. 160 – 162 °C. IR (ATR) = 3303, 3133, 2989, 1662, 1579, 1516, 1321, 1220, 1143, 
1092, 843, 621 cm-1. 1H NMR (400 Hz, CD3OD): δ 7.65 – 7.55 (m, 2H), 7.39 – 7.31 (m, 2H) ppm. 
13C{1H} NMR (100 Hz, CD3OD): δ 164.4 (d, J = 248 Hz), 156.6, 131.0 (d, J = 3 Hz), 128.0 (d, J = 9 




1-(pyridin-3-yl)-1H-tetrazol-5-amine (5h). Following the procedure described for the 5d, compound 
5h was obtained as a pale pink solid (230 mg, 27%) starting from 3-aminopyridine (500 mg, 5.31 
mmol); m.p. 145 – 146 °C. IR (ATR) = 3108, 1672, 1584, 1491, 14, 1435, 1124, 1079, 806, 720 cm-1. 
1H NMR (400 Hz, DMSO-d6): δ 8.85 – 8.77 (m, 1H), 8.77 – 8.71 (m, 1H), 8.08 – 8.02 (m, 1H), 7.69 – 
7.62 (m, 1H), 7.05 (s, 2H) ppm. 13C{1H} NMR (100 Hz, DMSO-d6): δ 155.3, 150.3, 145.2, 132.4, 
130.4, 124.6 ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ Calcd. for C6H7N6
+ 163.0727; Found 
163.0728. 
 
General procedure for the palladium catalyzed N-arylation reacton. General procedure A.  
N-(4-methoxyphenyl)-1-phenyl-1H-tetrazol-5-amine (7a).9b The previously reported procedure16 
was modified in a way that the reaction mixture was heated at 35 °C in an oil bath for 24 h.  
Compounds 1-phenyl-1H-tetrazol-5-amine 5a (41 mg, 0.25 mmol, 1.05 equiv) and 1-bromo-4-
methoxybenzene 6a (30 μL, 0.24 mmol, 1.0 equiv) were coupled in the presence of Pd2(dba)3 (11 mg, 
0.012 mmol, 10 mol % Pd), t-BuXPhos (20 mg, 0.048 mmol, 20 mol %) NaOt-Bu (24 mg, 0.25 mmol, 
1.05 equiv) and 1,4-dioxane (1 mL). Compound 7a was obtained after dry-flash column 
chromatography (SiO2: Hex/EtOAc = 7/3) as a pale yellow powder (63 mg, 98%); m.p. 132 – 133 °C. 
IR (ATR) = 3239, 3197, 3004, 1609, 1572, 1508, 1491, 1456, 1268, 1233, 1177, 1030, 811, 771 cm-1. 
1H NMR (400 Hz, CDCl3): δ 7.65 – 7.56 (m, 3H), 7.54 – 7.49 (m, 2H), 7.42 (d, J = 8.8 Hz, 2H), 6.87 
(d, J = 8.9 Hz, 2H), 6.40 (s, 1H), 3.79 (s, 3H) ppm. 13C{1H} NMR (100 Hz, CDCl3): δ 156.3, 152.3, 
133.0, 131.3, 130.6, 130.5, 124.8, 120.7, 114.6, 55.7 ppm.  
 
1-(4-Methoxyphenyl)-N-phenyl-1H-tetrazol-5-amine (7b).9b Following the general procedure A, 
compound 7b was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 7/3) as a pale 
yellow powder (57 mg, 89%) from 5b (48 mg, 0.25 mmol) and 6b (25 μL, 0.24 mmol); m.p. 166 – 169 
°C. IR (ATR) = 1612, 1574, 1497, 1250, 1104, 838, 747 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.50 – 
7.45 (m, 2H), 7.41 – 7.37 (m, 2H), 7.32 – 7.26 (m, 2H), 7.07 – 7.00 (m, 3H), 3.85 (s, 3H) ppm. 
13C{1H} NMR (100 MHz, CDCl3 + CD3OD): δ 161.1, 152.2, 138.3, 129.3, 126.9, 125.2, 123.3, 118.2, 
115.5, 55.8 ppm.  
 
N-(4-nitrophenyl)-1-phenyl-1H-tetrazol-5-amine (7c). Following the general procedure A, 
compound 7c was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as a 
yellow powder (94 mg, 88%) from 5a (64 mg, 0.40 mmol) and 6c (77 mg, 0.38 mmol); m.p. 185 – 186 
°C. IR (ATR) = 3266, 3098, 1623, 1582, 1534, 1493, 1333, 1255, 1109, 851 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 10.18 (s, 1H), 8.25 (d, J = 9.1 Hz, 2H), 7.86 (d, J = 9.1 Hz, 2H), 7.74 – 7.64 (m, 5H) 
ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 151.5, 146.3, 141.1, 132.8, 130.4, 130.0, 125.8, 125.2, 
117.5 ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ Calcd. for C13H11N6O2
+ 283.0938; Found 283.0943. 
 
1-(4-Nitrophenyl)-N-phenyl-1H-tetrazol-5-amine (7d). Following the general procedure A, 
compound 7d was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as a red 
powder (113 mg, 84%) from 5c (103 mg, 0.500 mmol) and 6b (50 µL mg, 0.48 mmol); m.p. 177 – 178 
°C. IR (ATR) = 3233, 3192, 3115, 1599, 1588, 1521, 1497, 1455, 1340, 1313, 1241, 1104, 855, 752 
cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.54 (s, 1H), 8.49 (d, J = 9.0 Hz, 2H), 8.02 (d, J = 9.0 Hz, 2H), 
7.63 – 7.58 (m, 2H), 7.37 – 7.32 (m, 2H), 7.06 – 7.01 (m, 1H) ppm. 13C{1H} NMR (100 MHz, DMSO-
d6): δ 152.4, 147.8, 139.6, 138.2, 128.9, 126.6, 125.2, 122.4, 118.4 ppm. HRMS (HESI/Orbitrap) m/z: 
[M + H]+ Calcd. for C13H11N6O2
+ 283.0938; Found 283.0945. 
 
1-(4-Methoxyphenyl)-N-(4-nitrophenyl)-1H-tetrazol-5-amine (7e). Following the general procedure 
A, compound 7e was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 7/3) as a 
yellow powder (47 mg, 60%) from 5b (50 mg, 0.26 mmol) and 6c (50 mg, 0.25 mmol); m.p. 237 °C. 
IR (ATR) = 3071, 3935, 1620, 1584, 1535, 1512, 1334, 1258, 1108, 749 cm-1. 1H NMR (400 MHz, 
DMSO-d6): δ 10.06 (s, 1H), 8.24 (d, J = 9.2 Hz, 2H), 7.86 (d, J = 9.2 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H), 
7.19 (d, J = 8.8 Hz, 2H), 3.87 (s, 3H) ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 160.6, 151.8, 
146.4, 141.0, 127.7, 125.3, 125.2, 117.4, 115.0, 55.7 ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ 
Calcd. for C14H13N6O3
+ 313.1044; Found 313.1051. 
 
N-(4-methoxyphenyl)-1-(4-nitrophenyl)-1H-tetrazol-5-amine (7f). Following the general procedure 
A, compound 7f was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 7/3) as an 
orange powder (58 mg, 74%) from 5c (54 mg, 0.26 mmol) and 6a (31 µL, 0.25 mmol); m.p. 98 – 99 
°C. IR (ATR) = 3278, 3086, 2959, 2927, 2856, 1727, 1616, 1577, 1511, 1463, 1340, 1295, 1257, 1113, 
1077, 1032, 854, 746 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.34 (s, 1H), 8.48 (d, J = 9.0 Hz, 2H), 
8.01 (d, J = 9.0 Hz, 2H), 7.50 (d, J = 9.0 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 3.73 (s, 3H) ppm. 13C{1H} 
NMR (100 MHz, DMSO-d6): δ 155.0, 152.8, 147.6, 138.3, 132.6, 126.5, 125.2, 120.6, 114.1, 55.2 
ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ Calcd. for C14H13N6O3
+ 313.1044; Found 313.1057. 
 
N-phenyl-1-(3-(trifluoromethyl)phenyl)-1H-tetrazol-5-amine (7g). Following the general procedure 
A, compound 7g was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 9/1) as a 
pale yellow powder (155 mg, 86%) from 5a (100 mg, 0.620 mmol) and 6d (82 µL, 0.59 mmol); m.p. 
103 – 106 °C. IR (ATR) = 3254, 3101, 3058, 1620, 1591, 1533, 486, 1463, 1339, 1320, 1292, 1150, 
1112, 1094, 1068, 805, 766, 697 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.68 (s, 1H), 8.05 (s, 1H), 
7.96 – 7.92 (m, 1H), 7.73 – 7.61 (m, 5H), 7.59 – 7.54 (m, 1H), 7.36 – 7.32 (m, 1H) ppm. 13C{1H} 
NMR (100 MHz, DMSO-d6): δ 152.0, 140.7, 132.9, 130.3, 130.1, 130.0, 129.6 (q, J = 31 Hz), 125.8, 
124.2 (q, J = 270 Hz), 121.8 (q, J = 1 Hz), 118.3 (q, J = 4 Hz), 114.4 (q, J = 4 Hz) ppm. HRMS 
(HESI/Orbitrap) m/z: [M + H]+ Calcd. for C14H11F3N5
+ 306.0961; Found 306.0976. 
 
N-phenyl-1-(3-(trifluoromethyl)phenyl)-1H-tetrazol-5-amine (7h). Following the general procedure 
A, compound 7h was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 9/1) as an 
orange powder (211 mg, 63%) from 5d (250 mg, 1.17 mmol) and 6b (115 µL, 1.10 mmol); m.p. 79 – 
81 °C. IR (ATR) = 3192, 3081, 3038, 2997, 1613, 1572, 1532, 1495, 1470, 1451, 1334, 1313, 1250, 
1161, 1135, 1098, 1073, 85, 749, 699 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.45 (s, 1H), 8.13 (s, 
1H), 8.04 – 7.98 (m, 2H), 7.92 – 7.87 (m, 1H), 7.63 – 7.58 (m, 2H), 7.36 – 7.30 (m, 2H), 7.04 – 6.99 
(m, 1H) ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 152.5, 139.7, 133.8, 131.3, 130.5 (q, J = 32 Hz), 
130.1, 128.9, 126.9 (q, J = 4 Hz), 123.6 (q, J = 217 Hz), 123.1 (q, J = 4 Hz), 122.3, 118.4 ppm. HRMS 
(HESI/Orbitrap) m/z: [M + H]+ Calcd. for C14H11F3N5
+ 306.0961; Found 306.0974. 
 
N-(3-fluorophenyl)-1-phenyl-1H-tetrazol-5-amine (7i). Following the general procedure A, 
compound 7i was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as an off-
white powder (121 mg, 91%) from 5a (90 mg, 0.56 mmol) and 6e (58 µL, 0.52 mmol); m.p. 152 – 154 
°C. IR (ATR): 3169, 3075, 2999, 2922, 1610, 1573, 1530, 1492, 1453, 1402, 1326, 1269, 1248, 1171, 
1148, 1121, 1092, 1073, 1046, 1021, 992, 963, 924, 864, 824, 768, 727, 686, 631, 535 cm-1. 1H NMR 
(400 MHz, DMSO-d6): δ 9.59 (s, 1H), 7.76 – 7.61 (m, 5H), 7.61 – 7.52 (m, 1H), 7.48 – 7.40 (m, 1H), 
7.39 – 7.30 (m, 1H), 6.89 – 6.77 (m, 1H) ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 162.4 (d, J = 
240 Hz), 152.0, 141.7 (d, J = 11 Hz), 132.9, 130.4 (d, J = 10 Hz), 130.2, 130.0, 125.7, 114.1 (d, J = 2 
Hz), 108.4 (d, J = 21 Hz), 105.0 (d, J = 27 Hz) ppm. HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for 
C13H11FN5
+ 256.0993; Found 256.0993. 
 
1-(3-Fluorophenyl)-N-phenyl-1H-tetrazol-5-amine (7j). Following the general procedure A, 
compound 7j was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as an off-
white powder (130 mg, 96%) from 5e (100 mg, 0.560 mmol) and 6b (55 µL, 0.53 mmol); m.p. 109 – 
110 °C. IR (ATR) 3429, 3201, 3085, 3044, 2993, 2925, 1604, 1571, 1534, 1494, 1466, 1451, 1401, 
1321, 1268, 1243, 1198, 1153, 1084, 1034, 1006, 984, 890, 865, 795, 747, 688, 523 cm-1. 1H NMR 
(400 MHz, DMSO-d6): δ 9.38 (s, 1H), 7.74 – 7.60 (m, 4H), 7.57 – 7.47 (m, 2H), 7.37 – 7.29 (m, 2H), 
7.05 – 6.99 (m, 1H) ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 162.2 (d, J = 244 Hz), 152.4, 139.7, 
134.2 (d, J = 11 Hz), 131.7 (d, J = 9 Hz), 128.8, 122.2, 122.1 (d, J = 4 Hz), 118.4, 117.1 (d, J = 21 Hz), 




N-(4-fluorophenyl)-1-phenyl-1H-tetrazol-5-amine (7k). Following the general procedure A, 
compound 7k was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as an off-
white powder (110 mg, 81%) from 5a (100 mg, 0.559 mmol) and 6f (55 µL, 0.53 mmol); m.p. 165 – 
167 °C. IR (ATR): 3244, 3213, 3178, 3126, 3069, 3038, 3001, 2961, 2912, 2826, 2773, 1620, 1575, 
1502, 1456, 1439, 1393, 1325, 1211, 1158, 1125, 1094, 1070, 1045, 1019, 992, 847, 814, 790, 770, 
729, 692, 643, 621, 585, 506 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.35 (s, 1H), 7.84 – 7.44 (m, 
7H), 7.24 – 7.10 (m, 2H) ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 157.5 (d, J = 237 Hz), 152.4, 
136.2 (d, J = 2 Hz), 133.0, 130.1, 129.9, 125.6, 120.2 (d, J = 8 Hz), 115.3 (d, J = 23 Hz) ppm. HRMS 
(HESI/Orbitrap) m/z: [M+H]+ Calcd. for C13H11FN5
+ 256.0993; Found 256. 0993. 
 
1-(4-Fluorophenyl)-N-phenyl-1H-tetrazol-5-amine (7l). Following the general procedure A, 
compound 7l was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as an off-
white powder (118 mg, 87%) from 5f (100 mg, 0.559 mmol) and 6b (55 µL, 0.53 mmol); m.p. 145 – 
147 °C. IR (ATR): 3260, 3207, 3125, 3095, 3060, 3010, 2940, 2866, 1620, 1575, 1539, 1508, 1462, 
1422, 1322, 1228, 1184, 1157, 1127, 1094, 1039, 1014, 994, 889, 841, 807, 751, 693, 632, 597, 536, 
501 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.29 (s, 1H), 7.80 – 7.70 (m, 2H), 7.66 – 7.58 (m, 2H), 
7.55 – 7.47 (m, 2H), 7.36 – 7.28 (m, 2H), 7.03 – 6.97 (m, 1H) ppm. 13C{1H} NMR (100 MHz, DMSO-
d6): δ 162.7 (d, J = 246 Hz), 152.5, 139.8, 129.4 (d, J = 3 Hz), 128.8, 128.6 (d, J = 9 Hz), 122.1, 118.2, 
116.9 (d, J = 23 Hz) ppm. HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for C13H11FN5
+ 256.0993; 
Found 256. 0994. 
 
N-(3-chlorophenyl)-1-phenyl-1H-tetrazol-5-amine (7m). Following the general procedure A, 
compound 7m was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as an 
off-yellow powder (60 mg, 88%) from 5a (42 mg, 0.26 mmol) and 6g (29 µL, 0.25 mmol); m.p. 114 – 
117 °C. IR (ATR): 3233, 3160, 3072, 3033, 2974, 1612, 1595, 1566, 1527, 1496, 1479, 1455, 1091, 
1072, 1020, 909, 872, 772, 766, 687 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.56 (s, 1H), 7.83 – 7.78 
(m, 1H), 7.71 – 7.61 (m, 5H), 7.60 – 7.55 (m, 1H), 7.38 – 7.32 (m, 1H), 7.08 – 7.03 (m, 1H) ppm. 
13C{1H} NMR (100 MHz, DMSO-d6): δ 151.9, 141.4, 133.2, 132.9, 130.5, 130.2, 130.0, 125.7, 121.6, 
117.6, 116.6 ppm. HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for C13H11ClN5
+ 272.0698; Found 
272.0706. 
 
1-(3-Chlorophenyl)-N-phenyl-1H-tetrazol-5-amine (7n). Following the general procedure A, 
compound 7n was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as an off-
yellow powder (58 mg, 85%) from 5g (51 mg, 0.26 mmol) and 6b (26 µL, 0.25 mmol); m.p. 96 – 98 
°C. IR (ATR): 3192, 3114, 3078, 3035, 2992, 2919, 1615, 1572, 1531, 1499, 1482, 1436, 1253, 1100, 
1086, 787, 768, 749, 693 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.39 (s, 1H), 7.86 (s, 1H), 7.75 – 
7.65 (m, 3H), 7.65 – 7.59 (m, 2H), 7.37 – 7.29 (m, 2H), 7.05 – 6.99 (m, 1H) ppm. 13C{1H} NMR (100 
MHz, DMSO-d6): δ 152.4, 139.7, 134.2, 134.0, 131.5, 130.2, 128.8, 126.0, 124.8, 122.2, 118.4 ppm. 
HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for C13H11ClN5
+ 272.0698; Found 272.0709. 
 
N-(1-phenyl-1H-tetrazol-5-yl)pyridin-3-amine (7o). Following the general procedure A, compound 
7o was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 6/4) as a pale yellow 
powder (50 mg, 84%) from 5a (42 mg, 0.26 mmol) and 6h (24 µL, 0.25 mmol); m.p. 125 – 126 °C. IR 
(ATR): 3258, 3051, 2962, 1611, 1570, 1532, 1499, 1486 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 9.58 
(s, 1H), 8.82 – 8.78 (m, 1H), 8.25 – 8.20 (m, 1H), 8.13 – 8.08 (m, 1H), 7.73 – 7.63 (m, 5H), 7.40 – 7.35 
(m, 1H) ppm. 13C{1H} NMR (100 MHz, DMSO-d6): δ 152.1, 143.1, 140.4, 136.7, 132.9, 130.2, 130.0, 
125.6, 125.1, 123.5 ppm. HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for C12H11N6
+ 239.1040; Found 
239.1044. 
 
N-phenyl-1-(pyridin-3-yl)-1H-tetrazol-5-amine (7p). Following the general procedure A, compound 
7p was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 6/4) as a pale yellow 
powder (41 mg, 69%) from 5h (43 mg, 0.26 mmol) and 6b (26 µL, 0.25 mmol); m.p. 115 – 117 °C. IR 
(ATR): 3263, 3205, 3121, 3090, 3044, 2924, 2853, 1611, 1571, 1533, 1501, 1434, 756, 696 cm-1. 1H 
NMR (400 MHz, DMSO-d6): δ 9.48 (s, 1H), 8.94 – 8.88 (m, 1H), 8.86 – 8.79 (m, 1H), 8.20 – 8.14 (m, 
1H), 7.74 – 7.69 (m, 1H), 7.66 – 7.59 (m, 2H), 7.37 – 7.30 (m, 2H), 7.05 – 6.99 (m, 1H) ppm. 13C{1H} 
NMR (100 MHz, DMSO-d6): δ 152.7, 151.0, 146.7, 139.6, 134.0, 130.2, 128.8, 124.7, 122.2, 118.3 
ppm. HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for C12H11N6
+ 239.1040; Found 239.1050. 
 
N-mesityl-1-phenyl-1H-tetrazol-5-amine (7q). Following the general procedure A, compound 7q was 
obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as a pale yellow powder (18 
mg, 27%) from 5a (41 mg, 0.25 mmol) and 6i (37 µL, 0.24 mmol); m.p. 90 – 97 °C. IR (ATR): 3172, 
3059, 2961, 2918, 2858, 1599, 1564, 1506, 1458, 1125, 1065, 760, 694 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 7.62 – 7.49 (m, 5H), 6.88 (s, 2H), 5.86 (s, 1H), 2.25 (s, 3H), 2.17 (s, 6H) ppm. 
13C{1H} 
NMR (100 MHz, CDCl3): δ 153.7, 137.6, 135.2, 133.3, 131.9, 130.4, 130.2, 129.5, 124.4, 21.0, 18.4 
ppm. HRMS (HESI/Orbitrap) m/z: [M+H]+ Calcd. for C16H18N5
+ 280.1557; Found 280.1567. 
 
2-Chloro-N-(1-phenyl-1H-tetrazol-5-yl)pyrimidin-4-amine (7r). Following the general procedure A, 
compound 7r was obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) colorless 
powder (30 mg, 44%) from 5a (42 mg, 0.26 mmol) and 6j (37 mg, 0.25 mmol). 
Compounds 1-phenyl-1H-tetrazol-5-amine 5a (42 mg, 0.26 mmol, 1.05 equiv) and 2,4-
dichloropyrimidine 6j (37 mg, 0.25 mmol, 1.0 equiv) were coupled in the presence of Pd2(dba)3 (11 
mg, 0.012 mmol, 10 mol % Pd), XantPhos (29 mg, 0.050 mmol, 20 mol %), K2CO3 (36 mg, 0.26 
mmol, 1.05 equiv) and 1,4-dioxane (3.2 mL) at 35 °C in an oil bath for 24 h. Compound 7r was 
obtained after dry-flash column chromatography (SiO2: Hex/EtOAc = 8/2) as a colorless powder (43 
mg, 63%); m.p. 140 – 141 °C. IR (ATR): 3228, 3134, 3045, 2980, 2917, 1613, 1589, 1523, 1506, 1486, 
1456, 1413, 1356, 1333, 1212, 988, 830, 769, 699, 682, 546 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.56 
(d, J = 4 Hz), 8.31 (d, J = 4 Hz), 7.71 – 7.64 (m, 3H), 7.56 – 7.49 (m, 2H) ppm. 13C{1H} NMR (100 
MHz, CDCl3): δ 161.0, 158.8, 149.6, 149.6, 131.8, 131.6, 131.0, 125.3, 106.8 ppm. HRMS 
(HESI/Orbitrap) m/z: [M+H]+ Calcd. for C11H9ClN7
+ 274.0602; Found 274.0616. 
 
General procedure for Dimroth-like rearrangement. General procedure B. 
A flame-dried reaction tube charged with compound 7 (10 mg) and 1,4-dioxane (0.5 mL) was sealed 
and the mixture was heated at 105 °C in an oil bath for 24 h. The reaction mixture was cooled to room 
temperature and the solvent was removed under the reduced pressure. Isomer ratio was determined by 
NMR spectroscopy (Table 3). 
NMR spectroscopic analysis in DMSO-d6: 
A flame-dried reaction tube charged with compound 7 (10 mg) and DMSO-d6 (0.5 mL) was sealed and 
the mixture was heated at 105 °C in an oil bath for 24 h. The reaction mixture was cooled to room 
temperature. Isomer ratio was determined by NMR spectroscopy (Table 3). 
 
N1-(1-phenyl-1H-tetrazol-5-yl)benzene-1,4-diamine (7t). A flame-dried round-bottom reaction flask 
was charged with compound 7c (15 mg, 0.053 mmol, 1 equiv) and deoxygenated methanol (1 mL) after 
which Pd/C (3 mg, 0.003 mmol, 5 mol % Pd) was added. The flask was closed with a rubber septum 
and the reaction mixture, connected to a balloon of hydrogen, was stirred at room temperature for 2 h. 
The reaction mixture was filtered and the solvent was removed under the reduced pressure to afford the 
pure 7t as an orange powder (13 mg, quant.); m.p. 93 – 94 °C. IR (ATR) = 3344, 1609, 1575, 1517, 
1497, 1458, 763 cm-1. 1H NMR (500 MHz, CD3OD): δ 7.65 – 7.58 (m, 5H), 7.20 (d, J = 8.8 Hz, 2H), 
6.71 (d, J = 8.8 Hz, 2H) ppm. 13C{1H} NMR (125 MHz, CD3OD): δ 155.1, 145.4, 134.7, 131.4, 131.2, 
131.1, 126.3, 123.5, 117.0 ppm. HRMS (HESI/Orbitrap) m/z: [M + H]+ Calcd. for C13H13N6
+ 
253.1196; Found 253.1208. 
 
1-(4-Aminophenyl)-N-phenyl-1H-tetrazol-5-amine (7u). Following the procedure described for the 
7t, compound 7u was obtained as a yellow solid (10 mg, quant) starting from 7d (12 mg, 0.041 mmol, 
1 equiv); m.p. 138 – 140 °C. IR (ATR) = 3640, 3476, 3063, 3254, 3236, 1610, 1576, 1528, 1501, 1319, 
836 cm-1. 1H NMR (500 MHz, CD3OD): δ 7.54 – 7.50 (m, 2H), 7.32 – 7.27 (m, 2H), 7.23 (d, J = 8.7 
Hz, 2H), 7.05 – 7.00 (m, 1H), 6.84 (d, J = 8.7 Hz, 2H) ppm. 13C{1H} NMR (125 MHz, CD3OD): δ 
154.4, 151.8, 140.9, 130.0, 127.9, 123.9, 123.0, 120.0, 116.1 ppm. HRMS (HESI/Orbitrap) m/z: [M + 
H]+ Calcd. for C13H13N6
+ 253.1196; Found 253.1206. 
 
Dimroth-like rearrangement of 7t to 7u. 
A flame-dried reaction tube charged with compound 7t (13 mg, 0.053 mmol) and 1,4-dioxane (0.5 mL) 
was sealed and the mixture was heated at 105 °C in an oil bath for 24 h. The reaction mixture was 
cooled to room temperature and the solvent was removed under the reduced pressure. NMR 
spectroscopy analysis showed a complete conversion of 7t to 7u. 
 
COMPUTATIONAL METHODS 
All DFT calculations were done with the Orca program package (version 4.1.2).26 The def2-TZVP(-f) 
basis set was used for all atoms. The SMD solvation model (with dioxane as solvent)27 was used in all 
calculations. Geometry optimizations were performed using general gradient functional consisting of 
Becke’s exchange28 and LYP correlation,29 with Grimme's fourth-generation dispersion energy 
corrections,30 i.e., BLYP-D4 functional. The resolution-of-the-identity approximation in the Split-RI-J 
variant and def2/J auxiliary basis sets was used. Numerical harmonic frequencies were calculated at the 
same level of theory to ascertain the nature of stationary points (minima or transition states). 
Vibrational analysis in quasi-harmonic approximation as proposed by Truhlar,31 with frequency cutoff 
100 cm-1, has been used to evaluate zero-point effects, entropic and thermal corrections to the Gibbs 
free energy. To assess the impact of the hybrid functional, single-point energies were computed with 
B3LYP-D4,32 with the chain-of-spheres approximation to the exact exchange, on the optimized BLYP-
D4/def2-TZVP(-f) geometries (see the Supporting Information, Table S3). 
 
ASSOCIATED CONTENT 
The Supporting Information is available free of charge on the ACS Publications website at DOI: 
10.1021/acs.joc. 
Copies of 1H and 13C NMR spectra for the synthesized compounds (PDF) 
Extended computational results, total electronic energies, number of imaginary frequencies and 






Andrea M. Nikolić: 0000-0003-1907-1565 
Jelena Stanić: 0000-0001-8781-5330 
Matija Zlatar: 0000-0002-3809-0940 
Maja Gruden: 0000-0002-0746-5754 
Boban Anđelković: 0000-0002-9522-1492 
Života Selaković: 0000-0003-0322-6884 
Vladimir Ajdačić: 0000-0002-3423-0862 
Igor M. Opsenica: 0000-0003-4942-4042 
 
Notes 
The authors declare no competing financial interest. 
 
ACKNOWLEDGMENT 
This research was financially supported by the Ministry of Education, Science and Technological 
Development of Republic of Serbia (Contract number: 451-03-9/2021-14/200168, 451-03-9/2021-
14/200288 and 451-03-9/2021-14/200026), and Serbian Academy of Sciences and Arts under strategic 
projects programme-grant agreement No. 01-2019-F65. 
The authors acknowledge the support of the FP7 RegPot project FCUB ERA GA No. 256716. The EC 
does not share responsability for the content of the article. 
 
REFERENCES 
1. Aulakh, G. K.; Sodhi, R. K.; Singh, M. An update on non-peptide angiotensin receptor antagonists 
and related RAAS modulators. Life Sci. 2007, 81, 615–639. 
2. Saltiel, E.; Brogden, R. N. Cefonicid Drugs 1986, 32, 222–259. 
3. Szulczyk, D.; Bielenica, A.; Głogowska, A.; Augustynowicz-Kopeć, E.; Dobrowolski, M.; 
Roszkowski, R.; Stępień, K.; Chrzanowska, A.; Struga, M. Development of (4-methoxyphenyl)-1H-
tetrazol-5-amine regioisomers as a new class of selective antitubercular agents. Eur. J. Med. Chem. 
2020, 186, 111882. 
4. Szulczyk, D.; Dobrowolski, M. A.; Roszkowski, P.; Bielenica, A.; Stefańska, J.; Koliński, M.; 
Kmiecik, S.; Jóźwiak, M.; Wrzosek, M.; Olejarz, W.; Struga, M. Design and synthesis of novel 1H-
tetrazol-5-amine based potent antimicrobial agents: DNA topoisomerase IV and gyrase affinity 
evaluation supported by molecular docking studies. Eur. J. Med. Chem. 2018, 156, 631–640. 
5. Ford, R. E.; Knowles, P.; Lunt, E.; Marshall, S. M.; Penrose, A. J.; Ramsden, C. A.; Summers, A. J. 
H.; Walker, J. L.; Wright, D. E. Synthesis and quantitative structure-activity relationships of 
antiallergic 2-hydroxy-N-1H-tetrazol-5-ylbenzamides and N-(2-hydroxypheny1)-1H-tetrazole-5-
carboxamides. J. Med. Chem. 1986, 29, 538‒549. 
6. Edmont, D.; Rocher, R.; Plisson, C.; Chenault, J. Synthesis and evaluation of quinolone 
carboxyguanidines as antidiabetic agents. Bioorg. Med. Chem. Lett. 2000, 10, 1831‒1834. 
7. Ehsani, A.; Mahjani, M. G.; Moshre, R.; Mostaanzadeh, H.; Shabani Shayeh, J. Electrochemical and 
DFT study on the inhibition of 316L stainless steel corrosion in acidic medium by 1-(4-nitrophenyl)-5-
amino-1H-tetrazole. RSC Adv. 2014, 4, 20031‒20037. 
8. a) Serebryanskaya, T. V.; Yung, T.; Bogdanov, A. A.; Shchebet, A.; Johnsen, S. A.; Lyakhov, A. S.; 
Ivashkevich, L. S.; Ibrahimava, Z. A.; Garbuzenco, T. S.; Kolesnikova, T. S.; Melnova, N. I.; Gaponik, 
P. N.; Ivashkevich, O. A. Synthesis, characterization, and biological evaluation of new tetrazole-based 
platinum(II) and palladium(II) chlorido complexes ‒ Potent cisplatin analogues and their trans isomers. 
J. Inorg. Biochem. 2013, 120, 44‒53. b)Tang, H.; Zhou, Z.; Li, Z.; Chen, S.; Wang, L.; Zhang, T. 
Copper (II) complexes of 1-methyl-5-aminotetrazole with different energetic anions: syntheses, crystal 
structures and properties. J. Energ. Mater. 2021, 39, 23–32.  
9. a) Bégué, D.; Dargelos, A; Wentrup, C. Aryl nitrile imines and diazo compounds. Formation of 
indazole, pyridine N-Imine, and 2-pyridyldiazomethane from tetrazoles. J. Org. Chem. 2020, 85, 7952–
7958. b) Nimnual, P.; Tummatorn, J.; Boekfa, B.; Thongsornkleeb, C.; Ruchirawat, S.; Piyachat, P.; 
Punjajom K. Construction of 5‑aminotetrazoles via in situ generation of carbodiimidium ions from 
ketones promoted by TMSN3/TfOH. J. Org. Chem. 2019, 84, 5603–5613. 
10. Krishnan, S.; Chatterjee, S.; Solanki, A.; Guha, N.; Singh, M. K.; Gupta, A. K.; Rai, D. K. 
Aminotetrazole-functionalized SiO2 coated MgO nanoparticle composites for removal of acid fuchsin 
dye and detection of heavy metal ions. ACS Appl. Nano Mater. 2020, 3, 11203–11216. 
11. a) Katritzky, A. R.; Rogovoy, B. V.; Kovalenko, K. V. A general route to 5-aminotetrazoles. J. 
Org. Chem. 2003, 68, 4941–4943. b) Yella, R.; Khatun, N.; Rout, S. K.; Patel, B. K. Tandem 
regioselective synthesis of tetrazoles and related heterocycles using iodine. Org. Biomol. Chem. 2011, 
9, 3235–3245. c) Guin, S.; Rout, S. K.; Gogoi, A.; Nandi, S.; Ghara, K. K.; Patel, B. K. Desulfurization 
Strategy in the Construction of azoles possessing additional nitrogen, oxygen or sulfur using a 
copper(I) catalyst.  Adv. Synth. Catal. 2012, 354, 2757‒2770. d) Xie, Y.; Guo, D.; Jiang, X.; Pan, H.; 
Wang, W.; Jin, T.; Mi, Z. An efficient method for the synthesis of substituted 5-aminotetrazoles from 
selenoureas using PhI(OAc)2. Tetrahedron Lett. 2015, 56, 2533‒2536. e) Pathare, R. S.; Ansari, A. J.; 
Verma, S.; Maurya, A.; Maurya, A. K.; Agnihotri, V. K.; Sharon, A.; Pardasani, R. T.; Sawant, D. M. 
Sequential Pd(0)/Fe(III) catalyzed azide‒isocyanide coupling/cyclization reaction: One-pot synthesis of 
aminotetrazoles. J. Org. Chem. 2018, 83, 9530‒9537. 
12. Surry, D. S.; Buchwald, S. L. Biaryl phosphane ligands in palladium-catalyzed amination. Angew. 
Chem. Int. Ed. 2008, 47, 6338–6361. 
13. Ruiz-Castillo, P.; Buchwald, S. L. Applications of palladium-catalyzed C–N cross-coupling 
reactions. Chem. Rev. 2016, 116, 12564–12649. 
14. Heravi, M. M.; Kheilkordi, Z.; Zadsirjan, V.; Heydari, M.; Malmir, M. Buchwald-Hartwig reaction: 
An overview. J. Organomet. Chem. 2018, 861, 17–104. 
15. Charles, M. D.; Schultz, P.; Buchwald, S. L. Efficient Pd-catalyzed amination of heteroaryl halides. 
Org. Lett. 2005, 7, 3965–3968. 
16. Nikolić, A. M.; Ajdačić, V.; Opsenica, I. M. Palladium-catalyzed N-arylation of 1-substituted-1H-
tetrazol-5-amines. J. Organomet. Chem. 2019, 880, 134–142. 
17. a) El Ashry, E. S. H.; Nadeem, S.; Shah M. R.; El Kilany Y. Recent advances in the Dimroth 
rearrangement: A valuable tool for the synthesis of heterocycles. Adv. Heterocycl. Chem. 2010, 101, 
161–228. b) Krajczyk, A.; Boryski, J. Dimroth rearrangement-Old but not outdated. Curr. Org. Chem. 
2017, 21, 2515–2529. c) Ferreira, V. F.; da Silva, T. d. B.; Pauli, F. P.; Ferreira, P. G.; Forezi, L. d. S. 
M.; Lima, C. G. d. S.; da Silva, F. d. C. Dimroth’s Rearrangement as a synthetic strategy towards new 
heterocyclic compounds. Curr. Org. Chem. 2020, 24, 1999–2018. d) El Ashry, E. S. H.; El Kilany, Y.; 
Rashed, N.; Assafir, H. Dimroth rearrangement: Translocation of heteroatoms in heterocyclic rings and 
its role in ring transformations of heterocycles. Adv. Heterocycl. Chem. 1999, 75, 79–164. e) L’abbé, 
G. Molecular rearrangements of five-membered ring heteromonocycles. J. Heterocycl. Chem. 1984, 21, 
627–638. 
18. Finnegan, W. G.; Henry, R. A.; Lieber, E. Preparation and isomerization of 5-alkylaminotetrazoles. 
J. Org. Chem. 1953, 18, 779–791. 
19. Garbrecht, W. L.; Herbst, R. M. The synthesis of certain 5-aminotetrazole derivatives. IV. The 
rearrangement of certain monosubstituted 5-aminotetrazole derivatives. J. Org. Chem. 1953, 18, 1269–
1282. 
20. Dimroth, O. Ueber intramolekulare umlagerungen. Justus Liebigs Ann. Chem. 1909, 364, 183–226.  
21. a) Henry, R. A.; Finnegan, W. G.; Lieber, E. Thermal isomerization of substituted 5-
aminotetrazoles. J. Am. Chem. Soc. 1954, 76, 88–93. b) Henry, R. A.; Finnegan, W. G.; Lieber, E. 
Kinetics of the isomerization of substituted 5-aminotetrazoles. J. Am. Chem. Soc. 1955, 77, 2264–2270. 
c) Leroy, G.; Sana, M. Note sur le mecanisme réactionnel de la transposition de Dimroth. Une étude ab 
initio. J. Heterocycl. Chem. 1982, 19, 943–944. d) Hegarty, A. F.; Tynan, N. M.; Fergus S. Rate-
determining nitrogen inversion in the isomerisation of isoimides to imides and azides to tetrazoles: 
direct observation of intermediates stabilized by trifluoroethyl groups. J. Chem. Soc., Perkin Trans. 2 
2002, 1328–1334. 
22. a) Kolos, N. N.; Paponov, B. V.; Orlov, V. D.; Lvovskaya, M. I.; Doroshenko, A. O.; Sishkin, O. V. 
Derivatives of Δ2-pyrazoline-products of 1,5-diaminotetrazole interaction with chalcone: Molecular 
structure and spectral properties. J. Mol. Struct. 2006, 785, 114–122. b) Brigas, A. F.; Clegg, W.; 
Dillon, C. J.; Fonesca, C. F. C.; Johnstone, R. A. W. Metal-assisted reactions. Part 29. Structure and 
hydrogenolysis of C–N bonds in derivatives of aromatic amines. Bond length and electronegativity 
changes from X-ray crystallographic data. J. Chem. Soc., Perkin Trans. 2 2001, 1315–1324. c) Li, Q.; 
Yu, M. H.; Xu, J.; Li, A. L.; Hu, T. L.; Bu, X. H. Two new metal-organic frameworks based on 
tetrazole-heterocyclic ligands accompanied by in-situ ligand formation. Dalton Trans. 2017, 46, 3223–
3228.  
23. a) Vorobiov, A. N.; Gaponik, P. N.; Petrov, P. T.; Ivashkevich, O. A. One-pot syntheses of 5-
amino-1-aryltetrazole derivatives. Synthesis 2006, 8, 1307–1312. b) Van Poecke, S.; Negri, A.; 
Janssens, J.; Solaroli, N.; Karlsson, A.; Gago, F.; Blazarini, J.; Van Calenbergh, S. Synthesis, modeling 
and evaluation of 3’-(1-aryl-1H-tetrazol-5-ylamino)-substituted 3’-deoxythymidine derivatives as 
potent and selective human mitochondrial thymidine kinase inhibitors. Org. Biomol. Chem. 2011, 9, 
892–901.  
24. a) Moderhack, D.; Goos, K. H.; Preu, L. Dimroth-umlagerung von iminen des 1,5-diaminotetrazols. 
Chem. Ber. 1990, 123, 1575–1577. b) Vasil’kova, N. O.; Filimonova, V. N.; Kriven’ko, V. P. One-pot 
synthesis of isomeric 2-hydroxyphenyl-substituted cycloalkatetrazolopyrimidines. Russ. J. Org. Chem. 
2017, 53, 639–641. c) L’abbé, G; Vandendriessche, A; Van Essche, G.; Toppet, S. Dimroth 
rearrangement of 5-hydrazino-1,2,3-triazoles and 5-hydrazinotetrazoles. Bull. Soc. Chim. Belg. 1988, 
97, 543–544. 
25. a) Vorobiov, A. N.; Gaponik, P. N.; Petrov, P. T.; Ivashkevich, O. A. One-pot syntheses of 5-
amino-1-aryltetrazole derivatives. Synthesis 2006, 1307–1312. b) Škoch, K.; Císařová, I.; Štěpnička, P. 
Selective gold‐catalysed synthesis of cyanamides and 1‐substituted 1H‐tetrazol‐5‐amines from 
isocyanides. Chem. Eur. J. 2018, 24, 13788–13791. c) Yella, R.; Khatun, N.; Rout, S. K.; Patel, B. K. 
Tandem regioselective synthesis of tetrazoles and related heterocycles using iodine. Org. Biomol. 
Chem. 2011, 9, 3235–3245. d) Yao, C-H.; Song, J-S.; Chen, C-T.; Yeh, T-K.; Hsieh, T-C.; Wu, S-H.; 
Huang, C-Y.; Huang, Y-L.; Wang, M-H.; Liu, Y-W.; Tsai, C-H.; Kumar, C. R.; Lee, J-C. Synthesis 
and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose Co-transporter 2 
inhibitors. Eur. J. Med. Chem. 2012, 55, 32–38. 
26. Neese, F. Software Update: The ORCA Program System, Version 4.0. Wiley Interdiscip. Rev. 
Comput. Mol. Sci. 2018, 8, e1327. 
27. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Universal Solvation Model Based on Solute Electron 
Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic 
Surface Tensions. J. Phys. Chem. B 2009, 113, 6378–6396. 
28. Becke, A. D. Density-Functional Exchange-Energy Approximation with Correct Asymptotic 
Behavior. Phys. Rev. A 1988, 38, 3098–3100.   
29. a) Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti Correlation-Energy Formula 
into a Functional of the Electron Density. Phys. Rev. B 1988, 37, 785–789. b) Johnson, B. G.; Gill, P. 
M. W.; Pople, J. A. The Performance of a Family of Density Functional Methods. J. Chem. Phys. 1993, 
98, 5612. c) Russo, T. V.; Martin, R. L.; Hay, P. J. Density Functional Calculations on First-Row 
Transition Metals. J. Chem. Phys. 1994, 101, 7729.  
30. Caldeweyher, E.; Ehlert, S.; Hansen, A.; Neugebauer, H.; Spicher, S.; Bannwarth, C.; Grimme, S. 
A Generally Applicable Atomic-Charge Dependent London Dispersion Correction. J. Chem. Phys. 
2019, 150, 154122. 
31. a) Zhao, Y.; Truhlar, D. G. Computational characterization and modeling of buckyball tweezers: 
Density functional study of concave-convex Π⋯π Interactions. Phys. Chem. Chem. Phys. 2008, 10, 
2813–2818. b) Ribeiro, R. F.; Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Use of solution-phase 
vibrational frequencies in continuum models for the free energy of solvation. J. Phys. Chem. B 2011, 
115, 14556–14562.  
32. Becke, A. D. Density-Functional Thermochemistry. III. The Role of Exact Exchange. J. Chem. 
Phys. 1993, 98, 5648–5652. 
 
